GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » PS Ratio

Nymox Pharmaceutical (Nymox Pharmaceutical) PS Ratio : (As of May. 06, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Nymox Pharmaceutical's share price is $0.27. Nymox Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00. Hence, Nymox Pharmaceutical's PS Ratio for today is .

The historical rank and industry rank for Nymox Pharmaceutical's PS Ratio or its related term are showing as below:

During the past 13 years, Nymox Pharmaceutical's highest PS Ratio was 4100.00. The lowest was 3.67. And the median was 467.06.

NYMXF's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.145
* Ranked among companies with meaningful PS Ratio only.

Nymox Pharmaceutical's Revenue per Sharefor the three months ended in Sep. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00.

During the past 13 years, Nymox Pharmaceutical's highest 3-Year average Revenue per Share Growth Rate was 91.30% per year. The lowest was -63.80% per year. And the median was 4.60% per year.

Back to Basics: PS Ratio


Nymox Pharmaceutical PS Ratio Historical Data

The historical data trend for Nymox Pharmaceutical's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical PS Ratio Chart

Nymox Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 262.00 1,100.00 - - -

Nymox Pharmaceutical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nymox Pharmaceutical's PS Ratio

For the Biotechnology subindustry, Nymox Pharmaceutical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's PS Ratio distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's PS Ratio falls into.



Nymox Pharmaceutical PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Nymox Pharmaceutical's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.27/0
=

Nymox Pharmaceutical's Share Price of today is $0.27.
Nymox Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Nymox Pharmaceutical  (OTCPK:NYMXF) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Nymox Pharmaceutical PS Ratio Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

NYMOX Appeals Deficiency Letter

By Stock market mentor Stock market mentor 01-06-2023

NYMOX Receives Deficiency Letter from NASDAQ

By PurpleRose PurpleRose 07-14-2022

Nymox Delisting from NASDAQ

By Marketwired 07-05-2023

Nymox Shareholder Update

By GuruFocusNews GuruFocusNews 12-13-2021

Nymox Provides Current Update

By sperokesalga sperokesalga 05-10-2023

NYMOX Updates Shareholders

By PurpleRose PurpleRose 07-15-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 05-23-2022

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

By GlobeNewswire GlobeNewswire 11-15-2021

NYMOX Receives RTF letter from FDA

By PurpleRose PurpleRose 07-12-2022